BioNTech (NASDAQ:BNTX) CEO Sells $4,628,250.00 in Stock

Key Points

• BioNTech CEO Ugur Sahin sold 45,000 shares at an average price of $102.85, generating $4.63 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 5.24%; he also sold 31,500 shares the following day.
• BioNTech shares fell 4.9% to $98.66 during the reported session. The company recently missed quarterly earnings and revenue estimates, posting a loss of $2.53 per share and revenue that declined 59.5% year over year.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $126 price target, although several firms recently lowered their targets or downgraded the stock.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 45,000 shares of the firm's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00. Following the transaction, the chief executive officer owned 813,209 shares of the company's stock, valued at approximately $83,638,545.65. The trade was a 5.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total transaction of $3,260,880.00.

BioNTech Trading Down 4.9%

Shares of BNTX traded down $5.10 during trading hours on Tuesday, hitting $98.66. 1,103,851 shares of the stock were exchanged, compared to its average volume of 1,114,410. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The business has a 50-day moving average of $96.82 and a 200-day moving average of $95.61. The firm has a market capitalization of $24.95 billion, a P/E ratio of -12.60 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million for the quarter, compared to the consensus estimate of $180.18 million. During the same period last year, the company posted ($1.60) EPS. The business's revenue was down 59.5% compared to the same quarter last year. On average, research analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Berenberg Bank cut their target price on shares of BioNTech from $155.00 to $140.00 and set a "buy" rating on the stock in a research note on Tuesday, May 12th. Jefferies Financial Group reissued a "buy" rating on shares of BioNTech in a research report on Monday, June 1st. Wall Street Zen downgraded BioNTech from a "hold" rating to a "sell" rating in a research note on Saturday, August 8th. BMO Capital Markets downgraded BioNTech from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $128.00 to $105.00 in a research note on Tuesday. Finally, Morgan Stanley cut their price target on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $126.00.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently modified their holdings of BNTX. Flossbach Von Storch SE purchased a new position in shares of BioNTech during the second quarter valued at approximately $207,142,000. BNP Paribas Financial Markets grew its position in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company's stock valued at $150,235,000 after buying an additional 474,796 shares during the period. Bank of America Corp DE grew its position in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after buying an additional 166,432 shares during the period. GSK plc purchased a new stake in BioNTech during the fourth quarter worth about $84,711,000. Finally, First Trust Advisors LP raised its position in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company's stock worth $74,658,000 after acquiring an additional 451,124 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.